The CUNY system has an affair regarding research on the effectiveness of an Alzheimer's disease drug, with allegation of conflict of interest and data manipulation - and then questions of due process in investigating the allegations.
It began with questions about data manipulation in Science.* That led to CUNY announcing an investigation.** When questions were raised about the procedures involved in the investigation, CUNY pulled back and said it would investigate the investigation.*** That appears to be where things are now.
Perhaps both cases suggest that research universities should have procedures in place so that if and when allegations of research misconduct arise, there isn't an ad hoc response. Creating a after-the-fact response on a case-by-case basis doesn't work well.
===
**https://www.nytimes.com/2023/10/14/health/alzheimers-drug-research-simufilam.html.
***https://www1.cuny.edu/mu/forum/2023/10/27/statement-from-the-city-university-of-new-york/.
No comments:
Post a Comment